Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8⁺ T cell stemness and antitumor immunity

Interleukin (IL)-2 and IL-21 dichotomously shape CD8⁺ T cell differentiation. IL-2 drives terminal differentiation, generating cells that are poorly effective against tumors, whereas IL-21 promotes stem cell memory T cells (TSCM) and antitumor responses. Here we investigated the role of metabolic pr...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 117; no. 11; pp. 6047 - 6055
Main Authors Hermans, Dalton, Gautam, Sanjivan, García-Cañaveras, Juan C., Gromer, Daniel, Mitra, Suman, Spolski, Rosanne, Li, Peng, Christensen, Stephen, Nguyen, Rosa, Lin, Jian-Xin, Oh, Jangsuk, Du, Ning, Veenbergen, Sharon, Fioravanti, Jessica, Ebina-Shibuya, Risa, Bleck, Christopher, Neckers, Leonard M., Rabinowitz, Joshua D., Gattinoni, Luca, Leonard, Warren J.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 17.03.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Interleukin (IL)-2 and IL-21 dichotomously shape CD8⁺ T cell differentiation. IL-2 drives terminal differentiation, generating cells that are poorly effective against tumors, whereas IL-21 promotes stem cell memory T cells (TSCM) and antitumor responses. Here we investigated the role of metabolic programming in the developmental differences induced by these cytokines. IL-2 promoted effector-like metabolism and aerobic glycolysis, robustly inducing lactate dehydrogenase (LDH) and lactate production, whereas IL-21 maintained a metabolically quiescent state dependent on oxidative phosphorylation. LDH inhibition rewired IL-2–induced effects, promoting pyruvate entry into the tricarboxylic acid cycle and inhibiting terminal effector and exhaustion programs, including mRNA expression of members of the NR4A family of nuclear receptors, as well as Prdm1 and Xbp1. While deletion of Ldha prevented development of cells with antitumor effector function, transient LDH inhibition enhanced the generation of memory cells capable of triggering robust antitumor responses after adoptive transfer. LDH inhibition did not significantly affect IL-21–induced metabolism but caused major transcriptomic changes, including the suppression of IL-21–induced exhaustion markers LAG3, PD1, 2B4, and TIM3. LDH inhibition combined with IL-21 increased the formation of TSCM cells, resulting in more profound antitumor responses and prolonged host survival. These findings indicate a pivotal role for LDH in modulating cytokine-mediated T cell differentiation and underscore the therapeutic potential of transiently inhibiting LDH during adoptive T cell-based immunotherapy, with an unanticipated cooperative antitumor effect of LDH inhibition and IL-21.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewers: M.A.C., City of Hope National Medical Center; and T.F., University of Pittsburgh.
2Present address: Unidad de Biomarcadores y Medicina de Precisión, Unidad Analítica, Instituto de Investigación Sanitaria Fundación Hospital La Fe, 46026 Valencia, Spain.
3D.G. and S.M. contributed equally to this work.
Contributed by Warren J. Leonard, January 16, 2020 (sent for review December 9, 2019; reviewed by Michael A. Caligiuri and Toren Finkel)
6Present address: Department of Inflammation and Immunology, Pfizer, Cambridge, MA 02139.
1D.H. and S.G. contributed equally to this work.
Author contributions: D.H., S.G., J.C.G.-C., D.G., S.M., R.S., P.L., R.N., J.-X.L., S.V., J.F., L.M.N., J.D.R., L.G., and W.J.L. designed research; D.H., S.G., J.C.G.-C., D.G., S.M., R.S., P.L., R.N., J.-X.L., J.O., N.D., S.V., J.F., R.E.-S., and C.B. performed research; L.M.N. contributed new reagents/analytic tools; D.H., S.G., J.C.G.-C., D.G., S.M., R.S., P.L., S.C., R.N., J.-X.L., S.V., J.F., C.B., J.D.R., L.G., and W.J.L. analyzed data; and D.H., S.G., J.C.G.-C., D.G., R.S., P.L., J.-X.L., C.B., L.M.N., J.D.R., L.G., and W.J.L. wrote the paper.
4Present address: Department of Medicine, Massachusetts General Hospital, Boston, MA 02114.
5Present address: University of Lille, UMR-S-1172-JPARc-Center de Researche Jean-Pierre Aubert Neuroscience et Cancer, F-59000 Lille, France.
7Present address: Laboratory of Pediatric Gastroenterology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1920413117